breast cancer therapy (Memorial Sloan-Kettering)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Namebreast cancer therapy (Memorial Sloan-Kettering)
Drug Alias Namegeldanamycin hybrids (Memorial Sloan-Kettering)LY-294002-GMPI3K-1-GM
ClassificationSmall molecules
Mechanisms of ActionApoptosis stimulantsProtein kinases inhibitorsAnticancer protein kinase inhibitors
TargetsProtein kinases
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMemorial Sloan Kettering Cancer Center
Active IndicationsN/A
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A